South Korea-based Hyundai Bioscience announced yesterday it has decided to submit a request for a fast track processing to the US Food and Drug Administration (FDA) for CP-COV03, an oral antiviral medicine for the treatment of monkeypox.
According to recently published research, Niclosamide, the active ingredient of CP-COV03, has already been shown to have excellent efficacy against the monkeypox type of virus.
Niclosamide-based CP-COV03, a cell-directed drug instead of other virus-directed drugs, is a broad-spectrum antiviral drug candidate that promotes cellular autophagy, which induces cells to recognize the virus as a foreign substance and then destroy it.
The scientific community considers the drug’s pharmacological mechanism of action applicable to many viral infections.
Researchers at Kansas State University published a study in the scientific journal Vaccines on July 21, 2020, in which Niclosamide demonstrably lowered the proliferation of vaccinia virus, a virus within the same family as the monkeypox virus, up to 100% level even at a concentration as low as one micromole.
Hyundai Bioscience confirmed on May 25, 2022, plans to submit data related to the results of animal studies of CP-COV03 to the FDA as swiftly as possible.
“CP-COV03 is a universal antiviral drug with niclosamide as the main ingredient, which can fight nearly all virus types,” commented Oh Sang Ki, CEO of Hyundai Bioscience in a related press statement.
“If CP-COV03 is approved as a treatment for monkeypox with the FDA’s fast-track designation, we will witness the birth of another innovative antiviral drug comparable to penicillin – the epitome of the 20th century’s ‘wonder antibiotics.”
Currently, SIGA Technologies’s TPOXX® (tecovirimat, ST-246®), a novel small-molecule drug, is approved in the US, Canada, UK, and Europe for the treatment of smallpox and monkeypox.
Monkeypox outbreak breaking news is posted at Vax-Before-Travel.
Note: The press release was manually curated for mobile readers.